Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.

  title={Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.},
  author={Carl Kyrklund and Janne T. Backman and Kari T. Kivist{\"o} and Mikko Neuvonen and Jouko Laitila and Pertti J Neuvonen},
  journal={Clinical pharmacology and therapeutics},
  volume={68 6},
BACKGROUND Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4. The cholesterol-lowering drug simvastatin has an extensive first-pass metabolism, and it is partially metabolized by CYP3A4. This study was conducted to investigate the effect of rifampin on the pharmacokinetics of simvastatin. METHODS In a randomized cross-over study with two phases and a washout of 4 weeks, 10 healthy volunteers received a 5-day pretreatment with rifampin (600 mg… CONTINUE READING